Deutsche Bank AG Sells 188,717 Shares of Schrodinger, Inc. $SDGR

Deutsche Bank AG cut its stake in shares of Schrodinger, Inc. (NASDAQ:SDGR) by 81.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 44,309 shares of the company’s stock after selling 188,717 shares during the period. Deutsche Bank AG owned about 0.06% of Schrodinger worth $875,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Schrodinger during the fourth quarter valued at $325,000. XTX Topco Ltd purchased a new position in Schrodinger in the fourth quarter worth about $199,000. CANADA LIFE ASSURANCE Co grew its stake in shares of Schrodinger by 4.2% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 72,765 shares of the company’s stock valued at $1,402,000 after purchasing an additional 2,904 shares during the period. MetLife Investment Management LLC increased its position in shares of Schrodinger by 5.6% during the 4th quarter. MetLife Investment Management LLC now owns 34,554 shares of the company’s stock valued at $667,000 after purchasing an additional 1,825 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Schrodinger by 8.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 42,009 shares of the company’s stock valued at $811,000 after purchasing an additional 3,376 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Schrodinger Price Performance

Shares of NASDAQ:SDGR opened at $20.32 on Monday. Schrodinger, Inc. has a 1-year low of $16.60 and a 1-year high of $28.47. The company has a market capitalization of $1.50 billion, a P/E ratio of -8.19 and a beta of 1.67. The firm’s 50 day simple moving average is $20.66 and its two-hundred day simple moving average is $22.11.

Schrodinger (NASDAQ:SDGR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. The firm had revenue of $54.76 million during the quarter, compared to analysts’ expectations of $52.03 million. Schrodinger had a negative net margin of 76.22% and a negative return on equity of 45.70%. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.66) earnings per share. On average, sell-side analysts anticipate that Schrodinger, Inc. will post -2.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SDGR. KeyCorp dropped their price objective on shares of Schrodinger from $32.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, July 14th. Barclays began coverage on shares of Schrodinger in a research note on Thursday, August 14th. They set an “overweight” rating and a $25.00 price target on the stock. Morgan Stanley cut their price objective on shares of Schrodinger from $28.00 to $19.00 and set an “equal weight” rating for the company in a research report on Monday, August 18th. Finally, Citigroup cut Schrodinger from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $20.00 in a report on Friday, August 15th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.83.

Schrodinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.